ECSP17072984A - Procesos farmacéuticos novedosos - Google Patents

Procesos farmacéuticos novedosos

Info

Publication number
ECSP17072984A
ECSP17072984A ECIEPI201772984A ECPI201772984A ECSP17072984A EC SP17072984 A ECSP17072984 A EC SP17072984A EC IEPI201772984 A ECIEPI201772984 A EC IEPI201772984A EC PI201772984 A ECPI201772984 A EC PI201772984A EC SP17072984 A ECSP17072984 A EC SP17072984A
Authority
EC
Ecuador
Prior art keywords
novel pharmaceutical
cab
pharmaceutical processes
vonoprazan
revaprazan
Prior art date
Application number
ECIEPI201772984A
Other languages
English (en)
Inventor
Richard Jenkins
Mark Hibberd
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17072984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1505526.2A external-priority patent/GB201505526D0/en
Priority claimed from GBGB1521015.6A external-priority patent/GB201521015D0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP17072984A publication Critical patent/ECSP17072984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un bloqueador de ácido competitivo con potasio (P-CAB) para usarse en el tratamiento, prevención y/o reducción de síntomas de la enfermedad por reflujo gastroesofágico (ERGE) en pacientes que responden de manera parcial a un inhibidor de la bomba de protones (IBP). El P-CAB puede, por ejemplo, seleccionarse de 1-[5- (2-fluorofenil)- 1-(piridin- 3-ilsulfonil)- 1H-pirrol- 3-il]- N-metilmetanamina (vonoprazan), revaprazan (YH1855), YH4808, RQ-4 y CS-526, o una sal de los mismos.
ECIEPI201772984A 2015-03-31 2017-10-31 Procesos farmacéuticos novedosos ECSP17072984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1505526.2A GB201505526D0 (en) 2015-03-31 2015-03-31 Novel pharmaceutical uses
GBGB1521015.6A GB201521015D0 (en) 2015-11-27 2015-11-27 Novel pharmaceutical uses

Publications (1)

Publication Number Publication Date
ECSP17072984A true ECSP17072984A (es) 2018-02-28

Family

ID=55806738

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201772984A ECSP17072984A (es) 2015-03-31 2017-10-31 Procesos farmacéuticos novedosos

Country Status (22)

Country Link
US (2) US20180085361A1 (es)
EP (1) EP3277279A1 (es)
JP (1) JP2018513140A (es)
KR (1) KR20170132260A (es)
CN (1) CN107530335A (es)
AU (1) AU2016241069A1 (es)
BR (1) BR112017021024A2 (es)
CA (1) CA2981244A1 (es)
CL (1) CL2017002325A1 (es)
CO (1) CO2017010019A2 (es)
CR (1) CR20170404A (es)
DO (1) DOP2017000218A (es)
EA (1) EA201792148A1 (es)
EC (1) ECSP17072984A (es)
IL (1) IL254419A0 (es)
MA (1) MA41850A (es)
MX (1) MX2017012414A (es)
PE (1) PE20180195A1 (es)
PH (1) PH12017501751A1 (es)
SG (1) SG11201706739WA (es)
TN (1) TN2017000416A1 (es)
WO (1) WO2016159386A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696893B2 (en) 2017-07-10 2023-07-11 Takeda Pharmaceutical Company Limited Preparation comprising vonoprazan

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1244791A1 (zh) 2015-03-31 2018-08-17 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
CN114642642A (zh) * 2020-12-18 2022-06-21 上海天慈生物谷生物工程有限公司 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲胺制剂
KR102851644B1 (ko) * 2021-07-28 2025-08-28 대봉엘에스 주식회사 보노프라잔 공형성화물, 및 이의 제조방법
CN119654147A (zh) * 2022-08-04 2025-03-18 江苏柯菲平医药股份有限公司 一种含有吡咯类胃酸分泌抑制剂的药物组合物及其制备方法
CN116270443A (zh) * 2022-10-27 2023-06-23 广州白云山天心制药股份有限公司 富马酸伏诺拉生注射液及其制备方法
CN115944743B (zh) * 2023-01-18 2025-08-08 山东诚成医药科技有限公司 一种富马酸伏诺拉生组合物及其制备方法
CN121622564A (zh) * 2024-09-04 2026-03-10 山东罗欣药业集团股份有限公司 一种焦谷氨酸替戈拉生注射液及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1784404T3 (da) 2004-09-03 2012-02-13 Yuhan Corp Pyrrolo[2,3-c]pyridinderivater samt fremgangsmåder til deres fremstilling
WO2008130863A2 (en) * 2007-04-11 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
CN104784180A (zh) 2008-07-28 2015-07-22 武田药品工业株式会社 药物组合物
EP2452680B1 (en) * 2009-07-09 2019-12-18 RaQualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
US20120070468A1 (en) * 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
JP6343600B2 (ja) 2013-02-28 2018-06-13 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
CN103951652B (zh) * 2014-04-18 2015-09-23 潍坊博创国际生物医药研究院 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲胺水溶性有机酸盐和注射剂及它们的制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696893B2 (en) 2017-07-10 2023-07-11 Takeda Pharmaceutical Company Limited Preparation comprising vonoprazan

Also Published As

Publication number Publication date
CO2017010019A2 (es) 2018-02-20
AU2016241069A1 (en) 2017-09-21
BR112017021024A2 (pt) 2018-07-03
SG11201706739WA (en) 2017-09-28
DOP2017000218A (es) 2018-01-31
EP3277279A1 (en) 2018-02-07
PE20180195A1 (es) 2018-01-26
US20180085361A1 (en) 2018-03-29
TN2017000416A1 (en) 2019-01-16
KR20170132260A (ko) 2017-12-01
CA2981244A1 (en) 2016-10-06
MX2017012414A (es) 2018-01-26
PH12017501751A1 (en) 2018-04-11
EA201792148A1 (ru) 2018-02-28
US20190070159A1 (en) 2019-03-07
WO2016159386A1 (en) 2016-10-06
MA41850A (fr) 2018-02-06
CN107530335A (zh) 2018-01-02
CR20170404A (es) 2018-01-10
JP2018513140A (ja) 2018-05-24
CL2017002325A1 (es) 2017-12-29
IL254419A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
DOP2017000218A (es) Usos farmacéuticos novedosos.
AR090269A1 (es) Composicion farmaceutica y sus usos
JO3653B1 (ar) ترايازول عوامل مساعدة لمستقبل apj
EA201892202A1 (ru) Способы лечения холестатических заболеваний
MX2017006275A (es) Inhibidor de cinasa aurora a.
MD4685B1 (ro) Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2
MX388251B (es) Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
EA201692470A1 (ru) Фармацевтические комбинации
WO2017208174A3 (en) Methods of treating disease with pfkfb3 inhibitors
DK3687567T3 (da) Anti-adrenomedullin (adm) bindemiddel til brug i behandling eller forebyggelse af sygdomssymptomer
MX388815B (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
CO2017008115A2 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico
BR112018011851A2 (pt) compostos de isoindol
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
CY1124397T1 (el) Κρυσταλλικο (2s,4r)-5-(5'-χλωρο-2-φθορο-[1,1'-διφαινυλ] -4-υλ)-2-(αιθοξυμεθυλ)-4-(3-υδροξυϊσοξαζολη-5- καρβοξαμιδο) -2-μεθυλπεντανοϊκο οξυ και χρησεις αυτου
MX376087B (es) Inhibidores macrocíclicos de cinasa rip2.
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета
JOP20210226A1 (ar) تركيبة صيدلانية تشتمل على مركب مشتق بنزيميدازول
CL2017002229A1 (es) Inhibidores de bace1.
EA201791456A1 (ru) Пептиды-антагонисты cgrp
EP3727397A4 (en) COMPOSITION AND METHOD OF TREATMENT, RELIEF OR PREVENTION OF NEUROPATHIC PAIN, WITH CHOLINAL FOSCERATE AS THE ACTIVE SUBSTANCE
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
EP3295947A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CHRONIC OBSTRUCTIVE LUNG DISEASE WITH, AS AN ACTIVE, FLOS MAGNOLIAE EXTRACT, FRACTION OR ACTIVE FRACTION THEREOF
AR103219A1 (es) Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento